Miami, FL 05/22/2013 (GDPInsider) - Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) opened the day at $2.97 and hit a high of $3.06 and a low of $2.83 and is currently down by 1.10% to trade at $2.69, with a volume of about 1.60 million.

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of ...

NEW YORK | Wed May 22, 2013 8:08am EDT. NEW YORK May 22 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares jump 10.3 percent to $3 in premarket after phase 2 metastatic melanoma trial results. Stocks · Markets · Healthcare ...

Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock gained 8.08% to $2.94. The company on May 22 announced preliminary results from its U.S.

CALGARY, May 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2013. ... Reaching the primary overall ...

CALGARY, May 14, 2013 /PRNewswire via COMTEX/ -- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TOR:CA:ONC) (NASDAQ:ONCY) , will present a corporate overview of the Company at the Bank of America Merrill Lynch Health Care Conference ...

CALGARY, May 6, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that its 2013 Annual and Special Meeting of Shareholders will be held on Thursday, May 9th, 2013 at 3:00 p.m.

Shares of Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) opened at $2.97 with 84.76 million outstanding shares and touched its highest price of $2.75 during the day and then finished at $2.75 by scoring +1.10%.

The company's relative strength index is currently at 79.45 which shows that the stock is overbought. SKS's price to earnings ratio is 35.97, with a market cap of $2.06 billion.

(Reuters) - Oncolytics Biotech Inc said preliminary data from a mid-stage trial showed that its cancer drug, Reolysin, met the main goal of reducing the size of tumors in patients with metastatic melanoma, a type of skin cancer.